Associated Genetic Biomarkers
INPP4A is altered in 1.32% of all cancers with lung adenocarcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in INPP4A are INPP4A Mutation (1.10%), INPP4A Amplification (0.10%), INPP4A Loss (0.02%), INPP4A R938Q (0.02%), and INPP4A A753T (0.01%) .
INPP4A status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains INPP4A status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with INPP4A status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are INPP4A Loss and INPP4A Mutation .
Paxalisib and radiation therapy are the most frequent therapies in trials with INPP4A as an inclusion criteria .
Significance of INPP4A in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.